The solution to democratize personalized cell therapies lies in automating their manufacturing process, which would reduce the cost, time, and risks significantly. This will require several engineering breakthroughs but is technically possible.
Imec's Liesbet Lagae wrote an opinion about the future of healthcare for the agenda section of the World Economic Forum's website:
Liesbet Lagae is imec Fellow and co-founder and Program Director of the Life Science Technologies in imec. In this role, she oversees the emerging R&D, the public funded activities and early business creation. She holds a PhD degree from the KU Leuven, Belgium for her work on Magnetic Random Access Memories. As a young group leader, she has initiated the field of molecular and cellular biochips leveraging silicon technologies at imec, Belgium. The life science program has grown from emerging activities to a mature business line that provides smart silicon chip solutions to the life science industry. Applications include medical diagnostics, point-of-care solutions, DNA sequencing, cytometry, bioreactors, neuroprobes, implants. She holds a prestigious ERC consolidator grant for developing a platform on single cell analysis and sorting. She has (co-) authored 125 peer-reviewed papers in international journals and holds 15 patents in the field. She is also part-time professor in nanobiotechnology at KU Leuven/Physics department.
More about these topics:
25 May 2021